ArticleJournal of medical case reports2025
A response of rituximab plus lenalidomide therapy in patients with post-transplant lymphoproliferative disease and methotrexate-related lymphoproliferative disorder in the central nervous system: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-transplant lymphoproliferative disorder and methotrexate-related lymphoproliferative disorder are rare complications normally with unfavorable prognosis. Post-transplant lymphoproliferative disorder of the central nervous system is a rare disorder and predominantly presents as diffuse large B-cell lymphomas of non-germinal center cell origin. However, the treatment for these patients with this diagnosis has not reached a consensus. CASE 1 AND 2 PRESENTATIONS: In this case report, one patient with post-transplant lymphoproliferative disorder and another patient with methotrexate-related lymphoproliferative disorder were both diagnosed with Epstein-Barr virus-diffuse large B-cell lymphomas of primary central nervous system. The former case was a 37-year-old Han Chinese female diagnosed with post-transplant lymphoproliferative disorder of the central nervous system after a kidney transplant, and the latter case was a 61-year-old Han Chinese male diagnosed with methotrexate-related lymphoproliferative disorder after receiving methotrexate treatment for psoriasis. The initial treatment for both of them was rituximab plus lenalidomide followed by lenalidomide as maintenance for disease progression or intolerance. After the treatment, magnetic resonance imaging showed partial response or complete remission of their brain lesions. In addition, the renal function of the patient with post-transplant lymphoproliferative disorder of the central nervous system was normal, and psoriasis did not recur in the patient with methotrexate-related lymphoproliferative disorder during lenalidomide maintenance treatment.
conclusionThe treatment has proved to be a promising therapeutic method for post-transplant lymphoproliferative disorder of the central nervous system and methotrexate-related lymphoproliferative disorder, when the decreasing or withdrawal of immunosuppressive therapy could not achieve a satisfying outcome. Owing to the relatively small sample size, the effect of this treatment should be further investigated under a larger sample size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.